I-Mab董事长傅唯回应公司转型更名等动作

Core Viewpoint - I-Mab is planning to conduct an initial public offering (IPO) in Hong Kong and aims for a dual listing on NASDAQ and the Hong Kong Stock Exchange, rebranding itself as NovaBridge Biosciences, with a focus on transforming into a platform-based enterprise rather than concentrating on single-target research [1][3]. Group 1: Company Transformation and Strategy - I-Mab's core transformation is to create an efficient platform-centric enterprise, leveraging its global vision and organizational resource integration capabilities to facilitate the internationalization of Chinese innovations [1][3]. - The company aims to become the best partner for clinical discovery by establishing multi-layered capital and funding cooperation with partners through various methods, including flexible equity acquisitions [3][12]. - I-Mab has a complete business development (BD) capability, having scanned hundreds of biotech companies and invested in over 30 of them in the past year, demonstrating a deep understanding of the structure and development pace of the Chinese biotech ecosystem [3][12]. Group 2: Financial Background and Market Position - I-Mab has raised over $500 million (approximately 3.23 billion RMB) since its inception, with significant funding rounds, including a $220 million Series C round in June 2018, which was one of the largest in China's innovative drug sector [4]. - However, the company faced a downturn after its IPO, with its market value plummeting from over $7 billion to approximately $754 million due to a tightening investment environment and the bursting of valuation bubbles [5][12]. - The company has been under pressure to restructure, including the transfer of its Chinese assets to a subsidiary, TJ Biopharma, to alleviate financial burdens and meet obligations to shareholders [5][12]. Group 3: Pipeline and Product Development - Following the asset split, I-Mab retained a limited pipeline, including a CD73 monoclonal antibody and two bispecific antibodies, but has faced challenges in advancing these projects [9][12]. - The company announced a pause in the development of its CD73 monoclonal antibody to focus on its bispecific antibody project, Givastomig, while also exploring new partnerships for its remaining assets [12][13]. - I-Mab is acquiring a new bispecific biologic, VIS-101, aimed at treating wet age-related macular degeneration and diabetic macular edema, through a newly established subsidiary, Visara, with an investment of approximately $37 million [13][14].